• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Sanofi-Aventis ADR

Sanofi-Aventis ADR

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. ADRs End Higher; Mining Firms Rise

    ADRs End Higher; Mining Firms Rise

  2. Medivation Has Rejected Buyout Approach From Sanofi -Bloomberg

    Medivation Has Rejected Buyout Approach From Sanofi -Bloomberg

  3. Low-Cost Exposure to U.S. Healthcare Firms

    This ETF holds a swath of large- and mid-cap U.S. healthcare companies.

  4. Our 2014 Big Pharma Pipeline Rankings: Who Came Out on Top?

    Merck's reinvigorated pipeline and Sanofi's minimal patent-loss exposure placed them atop our rankings this year, while GlaxoSmithKline joined Pfizer toward the bottom.

  5. 5 Wide-Moat Stocks That Were Left Behind in 2014

    It was a good year for wide-moat stocks overall, but Exxon, Amazon, and a few others lagged the market, says Morningstar markets editor Jeremy Glaser.

  6. Top 10 Purchases and Sales from Our Ultimate Stock-Pickers

    A group of top managers remains cautious and commits more capital to traditional defensive sectors, while taking advantage of a rising (and potentially overvalued) market to book some gains.

  7. Funds That Buy Like Buffett 2015

    Funds that emulate the Oracle of Omaha have done well over time.

  8. Health Care a Leader in Moat Stocks

    The health-care sector has a higher volume of moat firms compared with other industries, and companies' patent and brand power deliver very strong returns on capital.

  9. The Ultimate Stock-Pickers’ Top 10 Dividend Stocks

    Top managers continue to focus on higher-quality dividend-paying stocks in a fully valued market.

  10. Funds That Buy Like Buffett 2015

    Funds that emulate the Oracle of Omaha have done well over time.

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.